Abstract
Levomepromazine (previously known as methotrimeprazine), despite virtually no high quality scientific data to support its use, has become a very popular antiemetic for use in patients with advanced cancer. This article considers the reasons for this.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Dopamine Antagonists / adverse effects
-
Dopamine Antagonists / therapeutic use*
-
Humans
-
Methotrimeprazine / adverse effects
-
Methotrimeprazine / therapeutic use*
-
Nausea / drug therapy*
-
Nausea / etiology
-
Neoplasms / complications*
-
Palliative Care
-
Vomiting / drug therapy*
-
Vomiting / etiology
Substances
-
Dopamine Antagonists
-
Methotrimeprazine